Abstract: Corticosteroid compositions including a corticosteroid drug substance (e.g., fluocinolone, fluocinolone acetonide, dexamethasone, dexamethasone phosphate, dexamethasone sodium phosphate, triamcinolone, and triamcinolone acetonide) or a or a salt or derivative thereof and one or more irregular-shaped particulate fatty acid or keto-enol tautomer complexation agents admixed in a dispersal medium, having a release profile with one or more phases of drug release. These compositions are extended release corticosteroid compositions may release a clinically useful level of corticosteroid for more than 1 to 12 months within the body. Also described herein are methods of forming and methods of using these compositions.

Abstract: Described herein are therapeutic compositions and methods of use, for the delivery of various drug substances, in and around the eye, comprising: a drug substance, noncovalently interacting with one or more complexation agent particulates to form drug substance-complex particulates, admixed within a hydrophobic dispersal medium, that collectively forms a stable multiphasic colloidal suspension, that serves as an extended release drug delivery system for ocular drug delivery. Formulation of the drug substance in the multiphasic colloidal suspension can be administered in and around the eye to produce sustained release of therapeutic levels of drug substance within ocular tissues for one or more months without requiring retreatment.

Abstract: Described herein are therapeutic compositions for the treatment of mitochondrial disorders, and in particular mitochondrial disorders of the eye, including age-related macular degeneration (AMD). In particular, described herein are prodrugs of mitochondrial targeted tetrapeptides that have a cleavable covalent bond (e.g., an ester bond) to a conjugation moiety, wherein the conjugation moiety of the prodrug noncovalently complexes with one or more complexation agents to form drug-complex particulates with a defined avidity, and one or more drug-complex particulates are added to and dispersed within a dispersal medium forming a multiphasic colloidal suspension that serves as an extended release drug delivery system for ocular drug delivery. This extended release drug delivery system may be injected or inserted into the eye (e.g., vitreous) to reverse and prevent mitochondrial dysfunction in the eye for one or more months without requiring retreatment.

Abstract: To deliver surfactants or tracers to underground oil fields, inorganic encapsulated surfactant nanoparticles or microparticles that are stable for several weeks under high temperature and high salt conditions can be used.

Abstract: To deliver surfactants or tracers to underground oil fields, inorganic encapsulated surfactant nanoparticles or microparticles that are stable for several weeks under high temperature and high salt conditions can be used.